IgG4-Related Disease Manifested as Cutaneous Plasmacytosis: A Case Report

References

• Stone JH, Chan JK, Deshpande V, et al. Igg4-related disease. Int J Rheumatol. 2015;2013(6):539–551.
   Google Scholar
• Katz G, Stone JH. Clinical perspectives on IgG4-related disease and its classification. Annu Rev Med. 2022;73:545–562. doi:10.1146/annurev-med-050219-034449
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–1471. doi:10.1016/S0140-6736(14)60720-0
   PubMed Web of Science ®Google Scholar
• Wallace Z, Zhang Y, Perugino C, et al. Clinical phenotypes of igg4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406–412. doi:10.1136/annrheumdis-2018-214603
   PubMed Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for igg4-related disease (igg4-rd), 2011. Mod Rheumatol. 2012;22(1):21–30. doi:10.3109/s10165-011-0571-z
   PubMed Web of Science ®Google Scholar
• Abraham M, Khosroshahi A. Diagnostic and treatment workup for igg4-related disease. Expert Rev Clin Immunol. 2017;13(9):867–875. doi:10.1080/1744666X.2017.1354698
   PubMed Web of Science ®Google Scholar
• Sato Y, Takeuchi M, Takata K, et al. Clinicopathologic analysis of igg4-related skin disease. Mod Pathol. 2013;26(4):523–532. doi:10.1038/modpathol.2012.196
   PubMed Web of Science ®Google Scholar
• Kiyama M, Kaneko Y, Takeuchi T. Characteristics and prognosis of igg4-related periaortitis/periarteritis: a systematic literature review. Autoimmun Rev. 2019;18(9):102354. doi:10.1016/j.autrev.2019.102354
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Ohyama M. Tidying up the diversity of igg4‐related skin disease. Br J Dermatol. 2014;171(5):929. doi:10.1111/bjd.13394
   PubMed Web of Science ®Google Scholar
• Tokura Y, Yagi H, Yanaguchi H, Majima Y, Hashizume H. Igg4-related skin disease. Br J Dermatol. 2014;171(5):959–967. doi:10.1111/bjd.13296
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Hamid M, Mahajan VS, et al. Predictors of disease relapse in igg4-related disease following rituximab. Rheumatology. 2016;55(6):1000–1008. doi:10.1093/rheumatology/kev438
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Doglioni C. Immunology of igg4‐related disease. Clin Exp Immunol. 2015;181(2):191–206. doi:10.1111/cei.12641
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yasuoka H, Yamaoka K, et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther. 2016;18(1):167. doi:10.1186/s13075-016-1064-4
   PubMedGoogle Scholar
• Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin g4-related disease: a prospective study of 118 Chinese patients. Rheumatology. 2015;54(11):1982–1990. doi:10.1093/rheumatology/kev203
   PubMed Web of Science ®Google Scholar
• Mizushima I, Kasashima S, Fujinaga Y, Kawano M, Ishizaka N. IgG4-related periaortitis/periarteritis: an under-recognized condition that is potentially life-threatening. Mod Rheumatol. 2019;29(2):240–250. doi:10.1080/14397595.2018.1546367
   PubMed Web of Science ®Google Scholar
• Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev. 2015;268(1):139–159. doi:10.1111/imr.12349
   PubMed Web of Science ®Google Scholar
• Xu J, Bettendorf B, D’Oria M, Sharafuddin MJ. Multidisciplinary diagnosis and management of inflammatory aortic aneurysms. J Vasc Surg. 2022;78:SS0741–3. doi:10.1016/j.jvs.2022.12.024
   Web of Science ®Google Scholar
• Inoue D, Zen Y, Abo H, et al. Immunoglobulin g4-related periaortitis and periarteritis: CT findings in 17 patients. Radiology. 2011;261(2):625–633. doi:10.1148/radiol.11102250
   PubMed Web of Science ®Google Scholar
• Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of igg4-related systemic disease.Current Opinion in Rheumatology. Current Opinion in Rheumatology. 2011;23(1):88–94. doi:10.1097/BOR.0b013e3283412f7c
   PubMed Web of Science ®Google Scholar
• Ikawa T, Kasuya A, Hirakawa S, Tokura Y. Raynaud phenomenon, digital gangrene and hypergammaglobulinaemic purpura occurring in a patient with igg4‐related disease. Br J Dermatol. 2011;165(6):1364–1366. doi:10.1111/j.1365-2133.2011.10609.x
   PubMed Web of Science ®Google Scholar
• Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487–494. doi:10.1136/gutjnl-2016-312049
   PubMed Web of Science ®Google Scholar
• Omar D, Chen Y, Cong Y, Dong L. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology. 2020;59(4):718–726. doi:10.1093/rheumatology/kez380
   PubMed Web of Science ®Google Scholar
• Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4‐related disease: a randomized clinical trial. Rheumatology(Oxford). 2019;58(1):52‐60. doi:10.1093/rheumatology/key227
   Google Scholar
• Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4‐related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20(1):65. doi:10.1186/s13075-018-1567-2
   PubMedGoogle Scholar
• Zhang P, Gong Y, Liu Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4‐related diseases: a prospective clinical trial. Int J Rheum Dis. 2019;22(8):1479‐1488. doi:10.1111/1756-185X.13633
   Web of Science ®Google Scholar
• Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4‐related disease: a prospective, open‐label trial. Ann Rheum Dis. 2015;74(6):1171‐1177. doi:10.1136/annrheumdis-2014-206605
   Web of Science ®Google Scholar